【gmtlight】China's novel coronavirus mRNA vaccine (ARCoV) was developed by the Academy of military and the Local Academy of Sciences in June. 24, according to China's military network, Beijing, June. This is the first novel coronavirus mRNA vaccine approved for clinical trials in China.
Since China novel coronavirus pneumonia outbreak, the Academy of Military Medical Sciences of Chinese Academy of military science has been deploying emergency research, and has promoted the development of novel coronavirus vaccine for several technical routes. The novel coronavirus mRNA vaccine made in China is another high-tech vaccine which has been successfully developed and approved by the hospital after the recombinant novel coronavirus vaccine (adenovirus vector). The results showed that the novel coronavirus mRNA vaccine could not only induce high level neutralizing antibody in mice and cynomolgus monkeys, but also induce protective T cell immune response. The experimental results of cynomolgus monkeys showed that the vaccinated animals could tolerate the attack of high titer new coronavirus, effectively prevent virus replication and lung pathological progress, and show good protective effect.
MRNA vaccine is a new vaccine form in recent years. Its basic principle is to introduce the mRNA expressing antigen target into the body through a specific delivery system, express the protein in the body and stimulate the body to produce specific immune response, so that the body can obtain immune protection. There is a high technical threshold in the research and development of mRNA vaccine. At present, only a few kinds of mRNA vaccine developed in the United States and Germany have entered the clinical research stage. China has never approved the introduction of mRNA vaccine into clinical research before.
Qin Chengfeng, the project leader and researcher of the Academy of military medicine of the Academy of Military Sciences, said that the novel coronavirus mRNA vaccine made in China has three advantages: first, the vaccine antigen target selection is more accurate, the neutralizing antibody produced by induction is high in specificity, and the vaccine safety is better; second, the core raw materials and equipment are all made in China, which can realize the rapid expansion of production capacity; third, the single precharge is used The injection type can be stored at room temperature for one week or at 4 ℃ for a long time, with low cost of cold chain and easy to achieve mass vaccination.
It is reported that the novel coronavirus mRNA vaccine has been produced in multiple batches according to the requirements of clinical trials, and phase I clinical trials will be officially launched in Shulan (Hangzhou) hospital.
The novel coronavirus mRNA clinical trial is good news for the world to respond to the epidemic because China has promised that the vaccine will be open to the world.（gmtlight）